SEARCH:   Advanced

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Bergeron, R. J. Articles by Peter, H. H. Search for Related Content PubMed PubMed Citation Articles by Bergeron, R. J. Articles by Peter, H. H. Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model RJ Bergeron, RR Streiff, EA Creary, RD Daniels , W King, G Luchetta, J Wiegand, T Moerker and HH Peter Department of Medicinal Chemistry, Medicine, University of Florida, Gainesville 32610-0485. A comparative study of the iron-clearing properties of subcutaneously administered desferrioxamine B (DFO) with those of orally administered desferrithiocin sodium salt (1), desmethyl desferrithiocin (2), desazadesmethyl desferrithiocin sodium salt (3), desazadesmethyl desferrithiocin pivaloyloxymethyl ester (4), and desazadesmethyl-5,5- dimethyl desferrithiocin (5) in an iron-loaded Cebus monkey model and a non-iron overloaded bile duct-cannulated rat model is presented. All six drugs, which performed well in rodent studies, demonstrated increased efficiency in the Cebus monkey model. When administered to rodents at a daily dosage of 384 mumol/kg over a period of 10 days, drug 1 demonstrated severe renal toxicity. whereas drugs 3, 4, and 5 exhibited severe gastrointestinal (GI) toxicity. Under the same experimental protocol, drug 2 did not show significant toxic side effects. In addition, to further evaluate the iron-clearing properties of analogue 2, a dose-response study was performed in the primates that showed that iron excretion increased in a dose-dependent fashion. Volume 81, Issue 8, pp. 2166-2173, 04/15/1993 Copyright © 1993 by The American Society of Hematology CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: D. S. Kalinowski and D. R. Richardson The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer Pharmacol. Rev., December 1, 2005; 57(4): 547 - 583. [Abstract] [Full Text] [PDF] R. J. Bergeron, J. Wiegand, and G. M. Brittenham HBED ligand: preclinical studies of a potential alternative to deferoxamine for treatment of chronic iron overload and acute iron poisoning Blood, April 15, 2002; 99(8): 3019 - 3026. [Abstract] [Full Text] [PDF] R. J. Bergeron, W. R. Weimar, and J. Wiegand Pharmacokinetics of Orally Administered Desferrithiocin Analogs in Cebus apella Primates Drug Metab. Dispos., December 1, 1999; 27(12): 1496 - 1498. [Abstract] [Full Text] R. J. Bergeron, J. Wiegand, and G. M. Brittenham HBED: The Continuing Development of a Potential Alternative to Deferoxamine for Iron-Chelating Therapy Blood, January 1, 1999; 93(1): 370 - 375. [Abstract] [Full Text] [PDF] R. J. Bergeron, J. Wiegand, and G. M. Brittenham HBED: A Potential Alternative to Deferoxamine for Iron-Chelating Therapy Blood, February 15, 1998; 91(4): 1446 - 1452. [Abstract] [Full Text] [PDF] L. E. M. Cardoso and P. A. S. Mourao Compositional and Structural Alterations of Arterial Glycosaminoglycans Associated with the Complications Brought About by Thalassemia Major: A Case Report Angiology, February 1, 1996; 47(2): 175 - 183. [Abstract] [PDF]

	Copyright © 1993 by American Society of Hematology         Online ISSN: 1528-0020